IPSC250117P5000
- 0.00
- 0.000.00%
Century Therapeutics Newsroom
Piper Sandler Maintains Overweight on Century Therapeutics, Lowers Price Target to $4
Century Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $4
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $12
Analysts Are Bullish on Top Healthcare Stocks: Keros Therapeutics (KROS), Century Therapeutics (IPSC)
Leerink Partners Maintains Century Therapeutics(IPSC.US) With Buy Rating
Leerink Partners Maintains Century Therapeutics(IPSC.US) With Buy Rating
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $12
Century Therapeutics Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $5
Century Therapeutics Analyst Ratings
William Blair Maintains Century Therapeutics(IPSC.US) With Hold Rating
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $9
Century Therapeutics Analyst Ratings
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)
Buy Rating for Century Therapeutics Amidst Shift in Cell Therapy Market and Safety Concerns of Competitors
Century Therapeutics Analyst Ratings
Century Therapeutics Analyst Ratings